The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


YESCARTA

0.4 - 2x108 cells Dispersion for infusion

Kite Pharma EU B.V.EU/1/18/1299/001

Main Information

Trade NameYESCARTA
Active SubstancesAXICABTAGENE CILOLEUCEL
Strength0.4 - 2x108 cells
Dosage FormDispersion for infusion
Licence HolderKite Pharma EU B.V.
Licence NumberEU/1/18/1299/001

Group Information

ATC CodeL01X OTHER ANTINEOPLASTIC AGENTS

Status

Authorised/WithdrawnAuthorised
Licence Issued23/08/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back